Navigation Links
Researchers test new therapy for advanced melanoma

Melanoma is a particularly deadly form of skin cancer very resistant to treatment. Researchers at H. Lee Moffitt Cancer Center & Research Institute and the University of South Florida are testing a promising new therapy that prompts the immune system to aid in the fight against melanoma tumors.

"This is a milestone clinical trial because it is the first time that electroporation is being used to deliver plasmid DNA in a gene therapy study in humans," said Richard Heller, PhD, USF professor of medical microbiology and immunology who helped develop the technology used in the study.

Electroporation is a technique in which a hand-held device applied to the skin delivers pulses of electricity to open up pores in the tumor cell membrane. This opening allows a small therapeutic molecule -- in this case a molecule known as a DNA plasmid that contains the gene for Interleukin-12 -- to slip inside the melanoma tumor before the membrane reseals.

"Melanoma does not respond well to standard chemotherapy," said Adil Daud, MD, assistant professor of oncology in the Cutaneous Oncology Program at Moffitt. "Gene therapy gives us the flexibility to introduce a huge variety of potential targets for treatment, but its major limitation has been getting the gene into the cancer. If electroporation can deliver the gene to these tumors reliably and without serious side effects, melanoma and other cancers would be open to many new treatment possibilities."

Six years of laboratory studies by Dr. Heller and his colleagues preceded the initial human trial begun earlier this year at Moffitt. The collaboration of USF and Moffitt in this trial is a good example of translational research -- moving the new application of a gene transfer technology from an animal model to the patient. Dr. Heller's team worked extensively with Dr. Daud to adapt the electroporation technique used on mice to humans.

The researchers injected the DNA plasmid, which encodes a gene that stimulates the immune system, directly into the tumor site in mice. Then, they applied electroporation to the site to help the plasmid move into the tumor cells. The tumor cells used the plasmid's genetic instructions to make proteins. These proteins signaled the immune system to recognize the melanoma tumors as abnormal and attack.

Eighty percent of the mice were cured with this therapy -- their tumors disappeared and the treated animals remained disease free for the full length of the study (100 days), Dr. Heller said.

Furthermore, he said, even when melanoma cells were reinjected into the cured mice the tumors were rejected. This indicates the immune system formed a memory response that recognized the melanoma cells as foreign and prevented tumor regrowth.

"We were very encouraged by the results of the preclinical studies." Dr. Heller said. "We're hoping this translates into a beneficial treatment for patients."

The Phase 1 clinical trial by Moffitt and Genetronics Biomedical Corp is evaluating the safety of the electroporation technology in treating patients with advanced melanoma. The trial expects to enroll 18 to 25 patients.


'"/>

Source:University of South Florida Health Sciences Center


Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. Researchers reveal the infectious impact of salmon farms on wild salmon
5. Researchers identify target for cancer drugs
6. Researchers discover molecule that causes secondary stroke
7. Researchers find missing genes of ancient organism
8. Researchers trace evolution to relatively simple genetic changes
9. Researchers add new tool to tumor-treatment arsenal
10. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
11. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
(Date:12/16/2016)... Research and Markets has announced the addition ... to 2021" report to their offering. ... The biometric vehicle access system market, ... of 14.06% from 2016 to 2021. The market is estimated to ... 854.8 Million by 2021. The growth of the biometric vehicle access ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... YORK , Jan. 17, 2017 ... grow at a CAGR of around 7.5% over ... by 2025. Some of the prominent trends that ... growing incidences of diseases & graft transplant surgeries ... on Material the market is categorized into immunomodulatory ...
(Date:1/17/2017)... Mass. , Jan. 17, 2017   Pulmatrix, ... stage biopharmaceutical company developing innovative inhaled therapies to address ... for treating fungal infections in the lungs of CF ... Disease Product" (QIDP) by the U.S. Food & Drug ... which is designed to speed the development of novel ...
(Date:1/17/2017)... MANHASSET, N.Y. , Jan. 17, 2017 /PRNewswire-USNewswire/ ... to speed the advance of precision cancer research. ... State,s largest health care provider, Northwell ... each year. Indivumed, GmbH is a ... individualize anti-cancer medical therapies. Together they will greatly ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... global provider of learning and performance management systems for high-consequence industries, announced today ... , “In the life sciences industry, organizations must pay much more attention to ...
Breaking Biology Technology: